SAGE Therapeutics Inc
General ticker "SAGE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $335.5M
SAGE Therapeutics Inc does not follow the US Stock Market performance with the rate: -29.5%.
Estimated limits based on current volatility of 4.9%: low 5.06$, high 5.58$
Factors to consider:
- Company does not operate outside North America (retrieved using AI)
- Current price 54.5% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [11.96$, 29.12$]
- 2024-12-30 to 2025-12-30 estimated range: [9.99$, 23.16$]
Financial Metrics affecting the SAGE estimates:
- Negative: Non-GAAP EPS, $ of -8.50 <= 0.10
- Negative: Operating profit margin, % of -87.02 <= 1.03
- Negative: Operating cash flow per share per price, % of -30.37 <= 2.35
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Positive: Interest expense per share, $ of 0 <= 0
- Positive: Inventory ratio change, % of -87.65 <= -1.03
Short-term SAGE quotes
Long-term SAGE plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $6.31MM | $7.69MM | $86.45MM |
| Operating Expenses | $467.22MM | $554.67MM | $666.30MM |
| Operating Income | $-460.91MM | $-546.99MM | $-579.85MM |
| Non-Operating Income | $3.02MM | $14.21MM | $38.36MM |
| Interest Expense | $0.00MM | $14.19MM | $0.00MM |
| R&D Expense | $283.17MM | $326.16MM | $356.24MM |
| Income(Loss) | $-457.89MM | $-532.78MM | $-541.49MM |
| Profit(Loss) | $-457.89MM | $-532.78MM | $-541.49MM |
| Stockholders Equity | $1,729.03MM | $1,252.60MM | $799.53MM |
| Inventory | $18.51MM | $64.49MM | $1.50MM |
| Assets | $1,825.29MM | $1,356.45MM | $882.28MM |
| Operating Cash Flow | $-378.18MM | $-460.04MM | $-540.59MM |
| Capital expenditure | $0.37MM | $0.94MM | $0.55MM |
| Investing Cash Flow | $-1,002.45MM | $325.43MM | $442.91MM |
| Financing Cash Flow | $13.33MM | $3.07MM | $6.03MM |
| Earnings Per Share* | $-7.68 | $-8.49 | $-9.05 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.